Terms: = Pancreatic cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Treatment
46 results:
1. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
2. An orally available cancer drug AZD6738 prevents type 1 diabetes.
Sugitani N; Mason HR; Campfield BT; Piganelli JD
Front Immunol; 2023; 14():1290058. PubMed ID: 38164129
[TBL] [Abstract] [Full Text] [Related]
3. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract] [Full Text] [Related]
4. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in pancreatic cancer.
Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
[TBL] [Abstract] [Full Text] [Related]
5. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract] [Full Text] [Related]
6. The differential effect of neoadjuvant chemotherapy and chemoradiation on nodal downstaging in pancreatic adenocarcinoma.
Altimari M; Wells A; Abad J; Chawla A
Pancreatology; 2023 Nov; 23(7):805-810. PubMed ID: 37599170
[TBL] [Abstract] [Full Text] [Related]
7. Relationship between circulating tumour DNA and skeletal muscle stores at diagnosis of pancreatic ductal adenocarcinoma: a cross-sectional study.
Hanna L; Sellahewa R; Huggins CE; Lundy J; Croagh D
Sci Rep; 2023 Jun; 13(1):9663. PubMed ID: 37316578
[TBL] [Abstract] [Full Text] [Related]
8. Fast and label-free intraoperative discrimination of malignant pancreatic tissue by attenuated total reflection infrared spectroscopy.
Bandzeviciute R; Steiner G; Liedel K; Golde J; Koch E; Welsch T; Kahlert C; Stange DE; Distler M; Weitz J; Ceponkus J; Sablinskas V; Teske C
J Biomed Opt; 2023 Apr; 28(4):045004. PubMed ID: 37122477
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of combined pre- and postoperative albumin-to-alkaline phosphatase ratio for patients with hepatocellular carcinoma undergoing trans-catheter chemoembolisation.
Li J; Yang S; Li C; Zhu G; Xia J
Clin Radiol; 2023 Apr; 78(4):301-309. PubMed ID: 36690510
[TBL] [Abstract] [Full Text] [Related]
10. Characterizing gastrointestinal dysfunction after pancreatic resection: a single-center retrospective study.
Bromley-Dulfano R; August AT; Li AY; Park W; Visser B
BMC Gastroenterol; 2022 Nov; 22(1):488. PubMed ID: 36435757
[TBL] [Abstract] [Full Text] [Related]
11. Design, Synthesis, Kinetic Analysis and Pharmacophore-Directed Discovery of 3-Ethylaniline Hybrid Imino-Thiazolidinone as Potential Inhibitor of Carbonic Anhydrase II: An Emerging Biological Target for treatment of cancer.
Ahmed A; Aziz M; Ejaz SA; Channar PA; Saeed A; Zargar S; Wani TA; Hamad A; Abbas Q; Raza H; Kim SJ
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421710
[TBL] [Abstract] [Full Text] [Related]
12. ATM- and atr-induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma.
Chao YY; Huang BM; Peng IC; Lee PR; Lai YS; Chiu WT; Lin YS; Lin SC; Chang JH; Chen PS; Tsai SJ; Wang CY
J Cell Physiol; 2022 Dec; 237(12):4487-4503. PubMed ID: 36251015
[TBL] [Abstract] [Full Text] [Related]
13. Cell cycle checkpoints and beyond: Exploiting the atr/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
Gupta N; Huang TT; Horibata S; Lee JM
Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
[TBL] [Abstract] [Full Text] [Related]
14. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
[TBL] [Abstract] [Full Text] [Related]
15. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
[TBL] [Abstract] [Full Text] [Related]
16. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.
Healy GM; Salinas-Miranda E; Jain R; Dong X; Deniffel D; Borgida A; Hosni A; Ryan DT; Njeze N; McGuire A; Conlon KC; Dodd JD; Ryan ER; Grant RC; Gallinger S; Haider MA
Eur Radiol; 2022 Apr; 32(4):2492-2505. PubMed ID: 34757450
[TBL] [Abstract] [Full Text] [Related]
17. Homologous Recombination Deficiency in pancreatic cancer: A Systematic Review and Prevalence Meta-Analysis.
Casolino R; Paiella S; Azzolina D; Beer PA; Corbo V; Lorenzoni G; Gregori D; Golan T; Braconi C; Froeling FEM; Milella M; Scarpa A; Pea A; Malleo G; Salvia R; Bassi C; Chang DK; Biankin AV
J Clin Oncol; 2021 Aug; 39(23):2617-2631. PubMed ID: 34197182
[TBL] [Abstract] [Full Text] [Related]
18. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Shin DW; Lee JC; Kim J; Yoon YS; Han HS; Kim H; Hwang JH
Pancreatology; 2021 Jun; 21(4):796-804. PubMed ID: 33795193
[TBL] [Abstract] [Full Text] [Related]
19. Combinatorial Efficacy of Olaparib with Radiation and atr Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient pancreatic cancer.
Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
[TBL] [Abstract] [Full Text] [Related]
20. Targeting DNA Damage Response and Replication Stress in pancreatic cancer.
Dreyer SB; Upstill-Goddard R; Paulus-Hock V; Paris C; Lampraki EM; Dray E; Serrels B; Caligiuri G; Rebus S; Plenker D; Galluzzo Z; Brunton H; Cunningham R; Tesson M; Nourse C; Bailey UM; Jones M; Moran-Jones K; Wright DW; Duthie F; Oien K; Evers L; McKay CJ; McGregor GA; Gulati A; Brough R; Bajrami I; Pettitt S; Dziubinski ML; Candido J; Balkwill F; Barry ST; Grützmann R; Rahib L; ; ; Johns A; Pajic M; Froeling FEM; Beer P; Musgrove EA; Petersen GM; Ashworth A; Frame MC; Crawford HC; Simeone DM; Lord C; Mukhopadhyay D; Pilarsky C; Tuveson DA; Cooke SL; Jamieson NB; Morton JP; Sansom OJ; Bailey PJ; Biankin AV; Chang DK
Gastroenterology; 2021 Jan; 160(1):362-377.e13. PubMed ID: 33039466
[TBL] [Abstract] [Full Text] [Related]
[Next]
